You just read:

New data presented at American Society of Hematology (ASH) shows specific antidote idarucizumab* reverses dabigatran-induced anticoagulation independent of age, and kidney function

News provided by

Boehringer Ingelheim (Canada) Ltd.

Dec 18, 2014, 08:00 ET